SCHEMBL15723883

SCHEMBL15723883

CC(C)c1ncccc1C#CC1CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.41
GRM5 P41594 1/20 0.41
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
PTPN11 Q06124 1/20 0.33
POLB P06746 1/20 0.33
KCNH2 Q12809 1/20 0.33
PIK3CD O00329 3/20 0.32
PIK3CA P42336 3/20 0.32
PIK3CB P42338 3/20 0.32
PIK3CG P48736 3/20 0.32
PGK1 P00558 1/20 0.31
CREBBP Q92793 2/20 0.31
BRD4 O60885 1/20 0.31
MAPT P10636 1/20 0.31
XBP1 P17861 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15730262 0.79 CYP1A2 (0.47) CYP1A2GRM5NPC1RAB9ASMN1; SMN2
SCHEMBL18881216 0.77 PDK2 (0.44) PDK2
SCHEMBL31690840 0.76 CYP1A2 (0.44) CYP1A2GRM5ALDH1A1PTPN11KCNH2
SCHEMBL29856498 0.76 CYP1A2 (0.44) CYP1A2GRM5ALDH1A1PTPN11KCNH2
SCHEMBL18188415 0.76 GRM5 (0.44) CYP1A2GRM5SMN1; SMN2PTPN11KCNH2
SCHEMBL16432021 0.71 KDM4E (0.46) CYP1A2GRM5ALDH1A1SMN1; SMN2MAPT
SCHEMBL2627822 0.71 HPGD (0.53) CYP1A2ALDH1A1HPGDNPC1RAB9A
SCHEMBL13341844 0.71 ALDH1A1 (0.38) CYP1A2GRM5ALDH1A1HPGDNPC1
SCHEMBL3250054 0.71 ALDH1A1 (0.38) CYP1A2ALDH1A1HPGDNPC1RAB9A
SCHEMBL31690851 0.70 GRM5 (0.53) CYP1A2GRM5PTPN11KCNH2PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180194746-A1 Compounds For the Treatment of HIV GILEAD SCIENCES, INC. 2018-07-12 US disclosed
US-9944619-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2018-04-17 US disclosed
US-20170137405-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2017-05-18 US disclosed
US-9540343-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2017-01-10 US disclosed
US-20140142085-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 2014-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180194746-A1 Compounds For the Treatment of HIV CCR5, NPC1, FURIN CYP1A2 489/4885GRM5 3235/4885ALDH1A1 649/4885
US-20170137405-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN CYP1A2 489/4885GRM5 3235/4885ALDH1A1 649/4885
US-20140142085-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN CYP1A2 489/4885GRM5 3235/4885ALDH1A1 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.